HIV, HCV and HBV: A Review of Parallels and Differences

Leoni, Maria Cristina; Ustianowski, Andrew; Farooq, Hamzah Z.; Arends, Joop E.

doi:10.1007/s40121-018-0210-5

Cited by 21 publications

(21 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This review summarizes currently available nucleos(t)ide-based drugs and their acyclic analogues that exhibit multi-target activity https://doi.org/10. 1016/j.ejphar.2019.172747 Received 28 June 2019; Received in revised form 16 October 2019; Accepted 17 October 2019 HIV, HBV and HCV are three blood-borne viruses that cause emerging infectious diseases in humans worldwide (Leoni et al, 2018). According to the WHO, viral hepatitis caused 1.34 million deaths in 2015, a number that is comparable to the number of annual deaths caused by tuberculosis and that is even higher than those attributed to HIV.…”

Section: Introductionmentioning

confidence: 99%

“…Currently, HIV and HBV preventive strategies and treatment options are characterized by lifelong and chronic treatment, while for HCV, short-term and curative treatment is available. In contrast to HCV, for which a definitive cure has been developed because it does not persist in cells, the elimination of HBV and HIV infections worldwide is primarily hindered by their persistence in the host organism (Leoni et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Selected nucleos(t)ide-based prescribed drugs and their multi-target activity

Pastuch-Gawołek

Gillner

Król

et al. 2019

European Journal of Pharmacology

View full text Add to dashboard Cite

A B S T R A C T Nucleos(t)ide analogues play pivotal roles as antiviral, cytotoxic or immunosuppressive agents. Here, we review recent reports of nucleoside analogues that exhibit broad-spectrum activity towards multiple life-threatening RNA and DNA viruses. We also present a discussion about nucleoside antimetabolites-approved antineoplastic agents-that have recently been shown to have antiviral and/or antibacterial activity. The approved drugs and drug combinations, as well as recently identified candidates for investigation and/or experimentation, are discussed. Several examples of repurposed drugs that have already been approved for use are presented. This strategy can be crucial for the first-line treatment of acute infections or coinfections and for the management of drug-resistant strains.T against viral infections of great medical importance (e.g., herpes simplex virus (HSV), varicella zoster virus (VZV), human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV)) and/or that are known antineoplastic agents used to treat cancer. Approved nucleos(t)ide-based drugs with multi-target activity and compounds being tested in clinical trials or evaluated in preclinical assays are listed in Table 1. In this paper, the term "approval date" means the date on which the drug was approved by the US Food and Drug Administration (FDA) unless otherwise stated. G. Pastuch-Gawołek, et al. Multi-target nucleos(t)ide-based drugs in the treatment and prophylaxis of HIV, HBV and HCV infections

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Selected nucleos(t)ide-based prescribed drugs and their multi-target activity

Pastuch-Gawołek

Gillner

Król

et al. 2019

European Journal of Pharmacology

View full text Add to dashboard Cite

show abstract

“…Early pre‐DAA HCV treatment relied mainly on interferon and ribavirin with SVR rates between 25% and 50%. In contrast, the novel DAA therapies result in SVR in >95% of all HCV patients 32 . Although our observational retrospective study design cannot infer causation, the improvements in re‐LT outcomes found in this study are likely a result of DAA therapy.…”

Section: Discussionmentioning

confidence: 68%

Retransplantation outcomes for hepatitis C in the United States before and after direct-acting antiviral introduction

Ivanics

Rizzari

Moonka

et al. 2021

American Journal of Transplantation

View full text Add to dashboard Cite

The success of direct‐acting antiviral (DAA) therapy has led to near‐universal cure for patients chronically infected with hepatitis C virus (HCV) and improved post–liver transplant (LT) outcomes. We investigated the trends and outcomes of retransplantation in HCV and non‐HCV patients before and after the introduction of DAA. Adult patients who underwent re‐LT were identified in the Organ Procurement and Transplantation Network/United Network for Organ Sharing database. Multiorgan transplants and patients with >2 total LTs were excluded. Two eras were defined: pre‐DAA (2009‐2012) and post‐DAA (2014‐2017). A total of 2112 re‐LT patients were eligible (HCV: n = 499 pre‐DAA and n = 322 post‐DAA; non‐HCV: n = 547 pre‐DAA and n = 744 post‐DAA). HCV patients had both improved graft and patient survival after re‐LT in the post‐DAA era. One‐year graft survival was 69.8% pre‐DAA and 83.8% post‐DAA (P < .001). One‐year patient survival was 73.1% pre‐DAA and 86.2% post‐DAA (P < .001). Graft and patient survival was similar between eras for non‐HCV patients. When adjusted, the post‐DAA era represented an independent positive predictive factor for graft and patient survival (hazard ratio [HR]: 0.67; P = .005, and HR: 0.65; P = .004) only in HCV patients. The positive post‐DAA era effect was observed only in HCV patients with first graft loss due to disease recurrence (HR: 0.31; P = .002, HR 0.32; P = .003, respectively). Among HCV patients, receiving a re‐LT in the post‐DAA era was associated with improved patient and graft survival.

show abstract

“… 22 More importantly, HBV is often co-infected with HCV and HIV, resulting in a significant public health and socioeconomic burden all over the world, especially in underprivileged countries and regions. 23 , 24 Thus, early and rapid detection of HBV in suspected patients is essential to control infection by this pathogen. To date, ELISA and real-time PCR have been developed to identify HBV in clinical samples.…”

Section: Discussionmentioning

confidence: 99%

Multiple Cross Displacement Amplification Linked with Nanoparticles-Based Lateral Flow Biosensor in Screening of Hepatitis B Virus in Clinical Application

Chen¹,

Zhou²,

Dong³

et al. 2021

IDR

View full text Add to dashboard Cite

Background Hepatitis B virus (HBV) is a common pathogen that predominantly causes severe liver disease, and remains one of a huge challenge worldwide, especially in many resource-constrained areas. Developing a low-cost, sensitive, specific, and rapid approach for screening HBV is critical for its treatment and prevention. In the current study, a novel molecular detection approach, multiple cross displacement amplification (MCDA) coupled with polymer nanoparticle-based lateral flow biosensor (MCDA-LFB), was applied for detection of HBV in blood samples. Methods HBV standard substance and clinical donor serum samples were collected and used for the establishment and confirmation of the HBV-MCDA-LFB assay. A set of 10 MCDA primers was designed according to HBV-specific gene S . The HBV-MCDA-LFB assay conditions, including genomic template concentration, MCDA reaction temperature and time were optimized. The sensitivity and specificity of the HBV-MCDA -LFB assay were evaluated in this report. The HBV-MCDA-LFB assay was applied to detect the HBV agent from clinical samples. Results The HBV-MCDA primers based on the S gene were valid for establishment of MCDA assay. The HBV-MCDA reaction with optimized conditions could be carried out at a constant temperature 64°C for 35 min. The whole process, including sample preparation (5 min), genomic template extraction (~30 min), MCDA amplification (35 min), and LFB reading (~2 min), could be completed within 80 min. The sensitivity of this assay was 5 IU per reaction. The specificity was 100% for HBV-MCDA-LFB assay. Conclusion These results confirmed that the HBV-MCDA-LFB is a low-cost, sensitive, specific, simple, and rapid method for detecting HBV agents. This technique has great potential to develop a point-of-care testing (POCT) method in clinical practice, especially in endemic and resource-constrained regions.

show abstract

HIV, HCV and HBV: A Review of Parallels and Differences

Cited by 21 publications

References 67 publications

Selected nucleos(t)ide-based prescribed drugs and their multi-target activity

Selected nucleos(t)ide-based prescribed drugs and their multi-target activity

Retransplantation outcomes for hepatitis C in the United States before and after direct-acting antiviral introduction

Multiple Cross Displacement Amplification Linked with Nanoparticles-Based Lateral Flow Biosensor in Screening of Hepatitis B Virus in Clinical Application

Contact Info

Product

Resources

About